Clinical trials: Consolidation
Histoplasmosis
Histoplasmosis Induction and Consolidation Therapy Factorial Randomized Clinical Trial (Histo-FACT)
The purpose of the study is threefold: 1. Assess the safety and efficacy of a single high-dose intravenous (LAmB 10mg/kg) compared to the SOC daily dosing (3mg/kg) of the same medication for induction therapy in moderate to…
- Trial name
- NCT07261150
- Testing
- LAmB B, Posaconazole, World Health Organization (WHO)-recommended SOC
- Where
- 2 sites in United States, Brazil
- Volunteers
- 664 people
- Sponsor
- University of Minnesota
Patients With Acute Myeloid Leukemia, Patients Receiving Induction/Consolidation Chemotherapy
Genetic Predictive Model Based on Single Nucleotide Polymorphisms in the DNA Repair Pathway and Drug Metabolis/Transport Pharmacogenetics in the Prediction of Response and Treatment Outcomes in Acute Myeloid Leukemia
The main component in the treatment of acute myeloid leukemia (AML) is consist of anthracycline (such as daunorubicin or idarubicin) and cytarabine.
- Trial name
- NCT01106144
- Where
- South Korea
- Volunteers
- 500 people
- Sponsor
- Samsung Medical Center
STAGE IIIA/B NSCLC / INOPERABLE LUNG CANCER
Phase I/II NabPaclitaxel, Paclitaxel&Carboplatin w RTX Followed by Consolidation in Patients w Favorable Prognosis Inoperable Stage IIIA/B NSCLC
The investigators propose this phase I/II study to use weekly Nab-Paclitaxel (Abraxane) and carboplatin with concurrent radiation in local-regionally advanced lung cancer.
- Trial name
- NCT01757288
- Testing
- NAB-PACLITAXEL, PACLITAXEL
- Where
- 5 sites in United States
- Volunteers
- 98 people
- Sponsor
- University of Texas Southwestern Medical Center
Chronic Lymphocytic Leukemia, Leukemia
Alemtuzumab + Rituximab Consolidation in CLL
The goal of this clinical research study is to find out how well Campath (alemtuzumab), Rituxan (rituximab), or a combination of the 2 drugs may control Chronic Lymphocytic Leukemia (CLL) that is left after chemotherapy.
- Trial name
- NCT00771602
- Testing
- Rituximab, Alemtuzumab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- M.D. Anderson Cancer Center
Lymphoma
Donor T Cells, Low-Dose Aldesleukin, and Low-Dose GM-CSF After Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
RATIONALE: Giving high doses of chemotherapy before a donor stem cell transplant helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells.
- Trial name
- NCT00521261
- Testing
- anti-CD3 x anti-CD20 bispecific antibody-armed activated T cells
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Leukemia, Acute Lymphoblastic
Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)
B-precursor ALL is an aggressive malignant disease. Therapy is usually stratified according to risk characteristics to ensure that appropriate treatment is administered to patients with high-risk of relapse.
- Trial name
- NCT02393859
- Testing
- Blinatumomab, Dexamethasone, Vincrisitne
- Where
- 103 sites in Argentina, Australia and 22 more
- Volunteers
- 111 people
- Sponsor
- Amgen
Esophageal Neoplasms
Radiotherapy With or Without Concurrent Chemotherapy for Limited Lymphatic Metastasis of Esophageal Cancer - 3JECROG P-02
This phase III trial is designed to explore a higher radiation dose by using IMRT simultaneous integrated boost technique with or without concurrent chemotherapy for esophageal carcinoma with limited lymph node metastasis.
- Trial name
- NCT03308552
- Testing
- SIB-IMRT, Paclitaxel, Platinum-Based Drug
- Where
- China
- Volunteers
- 164 people
- Sponsor
- Chinese Academy of Medical Sciences
Chemotherapy
DCHA as Postremission Therapy for AML With t(8;21)
Acute myelocytic leukemia ( AML) is a highly heterogeneous group of malignant hematopathy. Chromosomal translocation with t (8; 21) (q22; q22) , about 10 ~ 15% incidence in AML and 40% incidence in the AML-M2 type of leukemia, is…
- Trial name
- NCT03453255
- Testing
- Chemotherapy
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Chinese PLA General Hospital
Acute Myelogenous Leukemia, Myelodysplastic Syndrome
A Randomized Trial of Procrit vs. No Procrit in AML and High Risk MDS
The goal of this clinical research study is to find out if Procrit (epoetin alfa) will help decrease the need for blood transfusions in patients who have Acute Myelogenous Leukemia (AML) or High-risk Myelodysplastic Syndrome…
- Conditions
- Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Leukemia
- Trial name
- NCT00656448
- Testing
- Procrit
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- M.D. Anderson Cancer Center
Elderly
Chronic Effects of Exercise on Motor Memory Consolidation in Elderly People
The main purpose of this study was to investigate if a six months period of physical exercise could improve motor memory consolidation in elderly people.
- Trial name
- NCT02731261
- Testing
- Motor memory consolidation
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Instituto Politécnico de Castelo Branco
Older Adults (50-90 Years)
Effects of Brain Stimulation During a Daytime Nap on Memory Consolidation in Older Adults
The beneficial effect of nocturnal as well as daytime sleep on memory consolidation is well-documented in young, healthy subjects.
- Trial name
- NCT01840839
- Testing
- brain stimulation
- Where
- Germany
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Charite University, Berlin, Germany
Diffuse Large B Cell Lymphoma
R-CHOP14 or R-CHOP21 &Consolidation PET-Oriented Radiotherapy (RT) in DLBCL Patients
Prospective, multicentre phase II study with R-CHOP- 14 or R-CHOP-21 \& consolidation PET-oriented radiotherapy (RT) in diffuse large B cell lymphoma (DLBCL) patients
- Trial name
- FIL_DLCL10 (NCT03364439)
- Testing
- Treatment plan
- Where
- 19 sites in Italy
- Volunteers
- 109 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Multiple Myeloma
Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)
Multiple myeloma is characterized by a pattern of recurrent relapse and remains an incurable malignancy. Participants with minimal residual disease (MRD) after front line therapy with induction and transplant have worse prognosis…
- Trial name
- ROTATE (NCT06993675)
- Testing
- Talquetamab, Teclistamab
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Noffar Bar
Epilepsy, Memory Consolidation
The Effect of Memory-Based Exercise and Planned Training Applied to Epilepsy Patients on Quality of Life
Epilepsy; It is a chronic, neurological disease that can occur regardless of social class, race and age. Every year, approximately 5 million people worldwide are diagnosed with epilepsy and 50 million people are affected by this…
- Conditions
- Epilepsy, Memory Consolidation, Education of Patients, Quality of Life (QOL)
- Trial name
- NCT06954922
- Testing
- memory-based exercise and training intervention, educational initiative about epilepsy
- Volunteers
- 50 people
- Sponsor
- Ataturk University
Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV
Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
The purpose of this study is to evaluate the therapeutic benefit and safety of subcutaneous (SC) Surovatamig monotherapy as consolidation therapy in patients with Chronic Lymphocytic Leukaemia (CLL)/ Small Lymphocytic Lymphoma…
- Trial name
- SOUNDTRACK-C1 (NCT07509151)
- Testing
- Surovatamig
- Where
- 44 sites in United States, Australia and 3 more
- Volunteers
- 420 people
- Sponsor
- AstraZeneca
Non-small Cell Lung Cancer Stage III, Borderline Resectable Carcinoma
Neoadjuvant Durvalumab and Chemotherapy Followed by Surgery/CRT and Durvalumab in Borderline Resectable Stage III NSCLC
A Phase II, interventional study of neoadjuvant durvalumab (MEDI 4736) and platinum-based Chemotherapy, followed by either surgery and adjuvant durvalumab or chemoradiotherapy (CRT) and consolidation durvalumab, in participants…
- Trial name
- ACCESS (NCT06998719)
- Testing
- Durvalumab
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Bi Nan
Bone Metastases, Fractures, Bone
EPIBONE Study: a Prospective Study on Feasibility, Safety and Accuracy
Interventional clinical study to obtain performance and safety data of the EPIONE® device when used for bone percutaneous procedures.
- Conditions
- Bone Metastases, Fractures, Bone, Bone Tumor
- Trial name
- EPIBONE (NCT06376682)
- Testing
- CT-guided bone percutaneous procedure
- Where
- 3 sites in France
- Volunteers
- 34 people
- Sponsor
- Quantum Surgical
Lymphoma, Large B-Cell, Diffuse
90Y-ibritumomab Tiuxetan Consolidation After 6th R-CHOP Chemotherapy in Patients With Bulky Diffuse Large B Cell Lymphoma
This phase II study is aimed at the clinical efficacy and toxicity of 6th R-CHOP chemotherapy followed by ibritumomab tiuxetan (Zevalin) consolidation in patients with limited-stage, bulky diffuse large B cell lymphoma (DLBCL).
- Trial name
- NCT01157988
- Testing
- ibritumomab tiuxetan (Zevalin)
- Where
- South Korea
- Volunteers
- 20 people
- Sponsor
- Chonnam National University Hospital
Attention Deficit Disorder With Hyperactivity
Sleep and Memory Consolidation in Adults With Attention Deficit Hyperactivity.
Attention Deficit Disorder With Hyperactivity is associated with deficits in cognition and sleep. In healthy adults, memory consolidation processes are related to sleep spindle activity in the sleep electroencephalogram.
- Trial name
- HYPNOS (NCT05876286)
- Testing
- Neurological examinations
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- University Hospital, Toulouse
Rectal Cancer, Consolidation
Chemoradiation and Consolidation Chemotherapy With or Without Oxaliplatin for Distal Rectal Cancer and Watch and Wait
Background: Neoadjuvant chemoradiation (nCRT) has been considered the preferred initial treatment strategy for distal rectal cancer.
- Trial name
- CCHOWW (NCT05000697)
- Testing
- Oxaliplatin, 5FU
- Where
- 24 sites in Argentina, Brazil and 1 more
- Volunteers
- 216 people
- Sponsor
- Hospital Alemão Oswaldo Cruz